The FDA prescribing information for Xeomin describes 20 units for horizontal forehead lines, given as 4 units at each of 5 sites, and directs that the forehead be treated together with the frown lines between the brows (another 20 units), for a maximum recommended dose of 40 units for the two areas. That labeled dose is a reference point, not a personal prescription. Your provider still has to decide whether treatment suits you and how your plan should look.
How many units of Xeomin for the forehead does the label describe?
Xeomin (incobotulinumtoxinA) is approved by the FDA for adults for the temporary improvement in the appearance of moderate to severe horizontal forehead lines associated with frontalis muscle activity. It is also approved for frown lines (glabellar lines) and crow's feet (lateral canthal lines).
For forehead lines, the label describes:
- Forehead: 4 units into each of 5 sites placed in a horizontal pattern in the frontalis muscle, for 20 units.
- Frown lines treated at the same visit: 4 units into each of 5 sites between the brows, for another 20 units.
- Maximum for forehead plus frown lines: 40 units.
- Maximum when crow's feet are also treated: 64 units in total (20 for frown lines, 20 for the forehead and 24 for crow's feet).
The label also says retreatment should happen no more often than every three months.
The labeled dose comes from clinical trials. In one trial, 92 adults received 20 units in the forehead and 20 units for frown lines. Thirty days later, 62% of them met the trial's definition of success for forehead lines: lines rated none or mild, with at least a two-grade improvement, judged by both the investigator and the participant. No one in the placebo group met that bar. That is a group result, not a prediction for your forehead.
How do brow position and facial muscles affect the exact dose?
Xeomin injections work by relaxing specific facial muscles. The label links horizontal forehead wrinkles to activity of the frontalis muscle, and frown lines to the corrugator and procerus muscles between the brows.
The label directs providers to treat forehead lines in conjunction with frown lines "to minimize the potential for brow ptosis," meaning a lowered or heavy-feeling brow. It also asks that forehead injections be placed at least 2 cm above the bony rim of the eye socket. This is one reason a forehead plan usually includes the area between the brows even when the forehead is your main concern. To reduce eyelid-droop risk, the label directs clinicians to place corrugator injections at least 1 cm above the bony ridge over the eye.
Brow position and eyelids are checked for the same reason. The Xeomin label asks providers to use caution in people who have:
- Marked facial asymmetry.
- Prior surgery that changed the facial anatomy.
- Drooping eyelids or brows before treatment.
- Excess upper-eyelid skin.
- Deep scarring in the skin, or thick, oily skin, such as lines that cannot be substantially lessened even by spreading them apart.
- Muscles that are already very weak or thin.
A unit count is only meaningful after this kind of assessment. If a provider proposes treating the forehead alone, or with a different pattern or number of units than the label describes, ask why, what the trade-offs are, and whether that part of the plan is on-label or off-label. Your provider will also want to know which other areas you plan to treat at the same visit, because each treatment area adds to the session total. The label says not to exceed the recommended maximum total dose in one treatment session.
Which contraindications, warnings and drug interactions matter?
The label lists two contraindications, meaning situations in which Xeomin should not be used: a known allergy to any botulinum toxin product or to any ingredient in the formulation, and an infection at a planned injection site, because it could lead to a severe local or widespread infection.
Its warnings and precautions section adds points that can change a forehead plan:
- Serious allergic reactions, including anaphylaxis, have been reported with botulinum toxin products.
- People who already have swallowing or breathing problems may be more susceptible to those complications.
- People with nerve and muscle disorders such as ALS, myasthenia gravis or Lambert-Eaton syndrome may be at increased risk of severe swallowing and breathing problems from typical doses.
- Providers should not exceed the recommended dosage and frequency of treatment.
The drug interactions section notes that some medicines can add to Xeomin's effect. Aminoglycoside antibiotics and other drugs that interfere with nerve-to-muscle signals may strengthen it. Muscle relaxants given before or after treatment may add to muscle weakness. Anticholinergic medicines taken afterward may increase anticholinergic side effects. The effect of receiving different botulinum toxin products at the same time, or within several months of each other, is unknown.
MedlinePlus advises telling your doctor about any botulinum toxin product you have received in the past four months, all medicines, vitamins and herbal products, bleeding problems, prior eye or face surgery, and conditions such as myasthenia gravis, ALS or Lambert-Eaton syndrome. Tell your provider if you are pregnant, planning a pregnancy or breastfeeding.
Can Xeomin units be compared with Botox or Dysport units?
No. The Xeomin label states that its units cannot be compared to or converted into units of any other botulinum toxin product. MedlinePlus likewise notes that one brand or type of botulinum toxin cannot be substituted for another.
That means a unit number you remember from a past treatment with a different product does not translate directly to Xeomin. When you discuss a plan, ask for the product name alongside the number of units, and ask how your provider chose the dose.
What side effects were reported in the forehead studies?
In two placebo-controlled trials of Xeomin for upper facial lines (frown lines, forehead lines and crow's feet), the most common adverse reaction reported more often with Xeomin than placebo was bruising at the injection site. Brow ptosis and injection-site discomfort were also reported. In the repeated-treatment phase of those trials, a collection of blood under the skin at the injection site (hematoma) was the most common reaction, followed by headache, bruising and brow ptosis. The label notes these reactions tended to become less frequent with later treatments.
The American Society for Dermatologic Surgery (ASDS) lists soreness, mild bruising, temporary weakness of surrounding muscles, headache and a drooping eyelid as possible side effects of neuromodulators, and advises not rubbing treated areas.
How long does the effect last?
The American Society of Plastic Surgeons (ASPS) notes that people may notice results within a few days, but that it can take up to a week to see the full effect of botulinum toxin. The American Academy of Dermatology (AAD) describes the effect as lasting about three to four months, and sometimes longer, with lines returning as muscle activity returns. These figures describe botulinum toxins in general; timing varies from person to person, and more units are not automatically better.
Follow the aftercare instructions your provider gives you. For general guidance, read aftercare precautions and when to call.
When should you get emergency help?
Xeomin, like all botulinum toxin products, carries a boxed warning that its effect may spread beyond the injection area and cause symptoms hours to weeks after treatment. Swallowing and breathing problems can be life-threatening.
Call 911 or go to an emergency room for trouble breathing, swallowing or speaking. Seek immediate medical evaluation for new double or blurred vision, widespread weakness or loss of bladder control. Contact your clinician immediately for new eyelid drooping. If your vision is blurred or your eyelids droop, the Medication Guide advises not driving or doing other dangerous activities.
For milder concerns, such as a brow that feels heavy, bruising or a headache, contact the treating provider for advice.
Questions to ask about your forehead plan
- Which product will you use, and is forehead treatment within its approved uses?
- How many units do you plan for my forehead and for the frown lines, and how does that compare with the label?
- Do my brows, eyelids, past procedures or skin type change the plan?
- Are you treating other areas at the same visit, and what is the total?
- When should we review the result, and when is the earliest I could have another Xeomin treatment?
- Which symptoms mean I should call you, and which mean emergency care?
Prepare with these neuromodulator consultation safety questions, explore facial aesthetics at Anew Laser MD, or use the contact page to ask whether Xeomin is offered at your location.
Independent sources
- FDA: Xeomin (incobotulinumtoxinA) prescribing information and Medication Guide, revised 06/2026
- MedlinePlus: incobotulinumtoxinA injection
- American Academy of Dermatology: botulinum toxin therapy FAQs
- American Society for Dermatologic Surgery: neuromodulators for frown lines and forehead furrowed brows
- American Society of Plastic Surgeons: botulinum toxin results
Learn about Facial Aesthetics at Anew Laser MD
General educational information is not a diagnosis or treatment recommendation. Consult a qualified clinician about your individual circumstances.
